 | • レポートコード：MRC2304A111 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、225ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医薬品 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の当調査レポートでは、2021年に389.0億ドルであった世界の抗糖尿病薬市場規模が2022年に429.8億ドルへと拡大、更に2027年までにCAGR 10.65％で成長して714.2億ドルに達すると予測しています。当書は、抗糖尿病薬の世界市場を総合的に分析し、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、種類別分析（α-グルコシダーゼ阻害剤、ビグアニド、DPP-IV（ジペプチジルペプチダーゼ）阻害剤、GLP-1（グルカゴン様ペプチド）アゴニスト、インスリン）、疾患別分析（1型糖尿病、2型糖尿病）、患者別分析（大人、高齢者、子供）、地域別分析（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）、競争状況、企業情報などの構成でまとめています。なお、当書には、Abbott Laboratories、Aristo Pharmaceuticals Pvt. Ltd.、Astellas Pharma Inc.、AstraZeneca PLC、Biocon Limited、C.H. Boehringer Sohn AG & Co. KG、Cadila Pharmaceuticals Limited、Cipla, Inc.、Eli Lilly and Company、F. Hoffmann-La Roche Ltd.などの企業情報が含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の抗糖尿病薬市場規模：種類別 - α-グルコシダーゼ阻害剤の市場規模 - ビグアニドの市場規模 - DPP-IV（ジペプチジルペプチダーゼ）阻害剤の市場規模 - GLP-1（グルカゴン様ペプチド）アゴニストの市場規模 - インスリンの市場規模 ・世界の抗糖尿病薬市場規模：疾患別 - 1型糖尿病における市場規模 - 2型糖尿病における市場規模 ・世界の抗糖尿病薬市場規模：患者別 - 大人における市場規模 - 高齢者における市場規模 - 子供における市場規模 ・世界の抗糖尿病薬市場規模：地域別 - 南北アメリカの抗糖尿病薬市場規模 アメリカの抗糖尿病薬市場規模 カナダの抗糖尿病薬市場規模 ブラジルの抗糖尿病薬市場規模 ... - アジア太平洋の抗糖尿病薬市場規模 日本の抗糖尿病薬市場規模 中国の抗糖尿病薬市場規模 インドの抗糖尿病薬市場規模 韓国の抗糖尿病薬市場規模 台湾の抗糖尿病薬市場規模 ... - ヨーロッパ/中東/アフリカの抗糖尿病薬市場規模 イギリスの抗糖尿病薬市場規模 ドイツの抗糖尿病薬市場規模 フランスの抗糖尿病薬市場規模 ロシアの抗糖尿病薬市場規模 ... - その他地域の抗糖尿病薬市場規模 ・競争状況 ・企業情報 |
The Global Antidiabetic Drugs Market size was estimated at USD 38.90 billion in 2021 and expected to reach USD 42.98 billion in 2022, and is projected to grow at a CAGR 10.65% to reach USD 71.42 billion by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Antidiabetic Drugs to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Type, the market was studied across Alpha-glucosidase Inhibitors, Biguanides, DPP-IV (Dipeptidyl Peptidase) Inhibitors, GLP-1 (Glucagon-like Peptide) Agonists, Insulin, Meglitinides, SGLT-II (Sodium Glucose Transport Proteins) Inhibitors, Sulphonylureas, and Thiazolidinedione. The Insulin is further studied across Intermediate-acting Insulin, Long-acting Analog, Premixed Insulin, Rapid-acting Analog, and Short-acting Analog.
Based on Disease, the market was studied across Diabetes Mellitus Type 1 and Diabetes Mellitus Type 2.
Based on Patient, the market was studied across Adult, Geriatric, and Pediatric.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Antidiabetic Drugs market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Antidiabetic Drugs Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Antidiabetic Drugs Market, including Abbott Laboratories, Aristo Pharmaceuticals Pvt. Ltd., Astellas Pharma Inc., AstraZeneca PLC, Biocon Limited, C.H. Boehringer Sohn AG & Co. KG, Cadila Pharmaceuticals Limited, Cipla, Inc., Eli Lilly and Company, F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Glenmark Pharmaceuticals Ltd., Halozyme Therapeutics, Inc., Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals), Mankind Pharma Ltd, Merck KGaA, Novo Nordisk A/S, Oramed Pharmaceuticals Inc., Pfizer Inc., PHC Corporation, Sanofi S.A., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., TONGHUA DONGBAO PHARMACEUTICAL CO., LTD., and Wockhardt Limited.
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Antidiabetic Drugs Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Antidiabetic Drugs Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Antidiabetic Drugs Market?
4. What is the competitive strategic window for opportunities in the Global Antidiabetic Drugs Market?
5. What are the technology trends and regulatory frameworks in the Global Antidiabetic Drugs Market?
6. What is the market share of the leading vendors in the Global Antidiabetic Drugs Market?
7. What modes and strategic moves are considered suitable for entering the Global Antidiabetic Drugs Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Changing lifestyle of people and irregular dietary habits
5.1.1.2. Strong product pipeline of antidiabetics
5.1.1.3. Globally rising prevalence of diabetes and increasing obesity among people
5.1.1.4. Increasing consumer awareness level and improved technology
5.1.2. Restraints
5.1.2.1. Prohibitive cost of Insulin
5.1.3. Opportunities
5.1.3.1. Advancement in the healthcare and pharmaceutical sectors
5.1.3.2. Ongoing research and development
5.1.3.3. Governments and private companies to work together for the supply of inexpensive drugs
5.1.4. Challenges
5.1.4.1. Wide availability of antidiabetics drugs
5.2. Cumulative Impact of COVID-19
6. Antidiabetic Drugs Market, by Type
6.1. Introduction
6.2. Alpha-glucosidase Inhibitors
6.3. Biguanides
6.4. DPP-IV (Dipeptidyl Peptidase) Inhibitors
6.5. GLP-1 (Glucagon-like Peptide) Agonists
6.6. Insulin
6.7.1. Intermediate-acting Insulin
6.7.2. Long-acting Analog
6.7.3. Premixed Insulin
6.7.4. Rapid-acting Analog
6.7.5. Short-acting Analog
6.7. Meglitinides
6.8. SGLT-II (Sodium Glucose Transport Proteins) Inhibitors
6.9. Sulphonylureas
6.10. Thiazolidinedione
7. Antidiabetic Drugs Market, by Disease
7.1. Introduction
7.2. Diabetes Mellitus Type 1
7.3. Diabetes Mellitus Type 2
8. Antidiabetic Drugs Market, by Patient
8.1. Introduction
8.2. Adult
8.3. Geriatric
8.4. Pediatric
9. Americas Antidiabetic Drugs Market
9.1. Introduction
9.2. Argentina
9.3. Brazil
9.4. Canada
9.5. Mexico
9.6. United States
10. Asia-Pacific Antidiabetic Drugs Market
10.1. Introduction
10.2. Australia
10.3. China
10.4. India
10.5. Indonesia
10.6. Japan
10.7. Malaysia
10.8. Philippines
10.9. Singapore
10.10. South Korea
10.11. Taiwan
10.12. Thailand
10.13. Vietnam
11. Europe, Middle East & Africa Antidiabetic Drugs Market
11.1. Introduction
11.2. Denmark
11.3. Egypt
11.4. Finland
11.5. France
11.6. Germany
11.7. Israel
11.8. Italy
11.9. Netherlands
11.10. Nigeria
11.11. Norway
11.12. Poland
11.13. Qatar
11.14. Russia
11.15. Saudi Arabia
11.16. South Africa
11.17. Spain
11.18. Sweden
11.19. Switzerland
11.20. Turkey
11.21. United Arab Emirates
11.22. United Kingdom
12. Competitive Landscape
12.1. FPNV Positioning Matrix
12.1.1. Quadrants
12.1.2. Business Strategy
12.1.3. Product Satisfaction
12.2. Market Ranking Analysis, By Key Player
12.3. Market Share Analysis, By Key Player
12.4. Competitive Scenario
12.4.1. Merger & Acquisition
12.4.2. Agreement, Collaboration, & Partnership
12.4.3. New Product Launch & Enhancement
12.4.4. Investment & Funding
12.4.5. Award, Recognition, & Expansion
13. Company Usability Profiles
13.1. Abbott Laboratories
13.1.1. Business Overview
13.1.2. Key Executives
13.1.3. Product & Services
13.2. Aristo Pharmaceuticals Pvt. Ltd.
13.2.1. Business Overview
13.2.2. Key Executives
13.2.3. Product & Services
13.3. Astellas Pharma Inc.
13.3.1. Business Overview
13.3.2. Key Executives
13.3.3. Product & Services
13.4. AstraZeneca PLC
13.4.1. Business Overview
13.4.2. Key Executives
13.4.3. Product & Services
13.5. Biocon Limited
13.5.1. Business Overview
13.5.2. Key Executives
13.5.3. Product & Services
13.6. C.H. Boehringer Sohn AG & Co. KG
13.6.1. Business Overview
13.6.2. Key Executives
13.6.3. Product & Services
13.7. Cadila Pharmaceuticals Limited
13.7.1. Business Overview
13.7.2. Key Executives
13.7.3. Product & Services
13.8. Cipla, Inc.
13.8.1. Business Overview
13.8.2. Key Executives
13.8.3. Product & Services
13.9. Eli Lilly and Company
13.9.1. Business Overview
13.9.2. Key Executives
13.9.3. Product & Services
13.10. F. Hoffmann-La Roche Ltd.
13.10.1. Business Overview
13.10.2. Key Executives
13.10.3. Product & Services
13.11. GlaxoSmithKline PLC
13.11.1. Business Overview
13.11.2. Key Executives
13.11.3. Product & Services
13.12. Glenmark Pharmaceuticals Ltd.
13.12.1. Business Overview
13.12.2. Key Executives
13.12.3. Product & Services
13.13. Halozyme Therapeutics, Inc.
13.13.1. Business Overview
13.13.2. Key Executives
13.13.3. Product & Services
13.14. Johnson & Johnson Services, Inc. (Janssen Pharmaceuticals)
13.14.1. Business Overview
13.14.2. Key Executives
13.14.3. Product & Services
13.15. Mankind Pharma Ltd
13.15.1. Business Overview
13.15.2. Key Executives
13.15.3. Product & Services
13.16. Merck KGaA
13.16.1. Business Overview
13.16.2. Key Executives
13.16.3. Product & Services
13.17. Novo Nordisk A/S
13.17.1. Business Overview
13.17.2. Key Executives
13.17.3. Product & Services
13.18. Oramed Pharmaceuticals Inc.
13.18.1. Business Overview
13.18.2. Key Executives
13.18.3. Product & Services
13.19. Pfizer Inc.
13.19.1. Business Overview
13.19.2. Key Executives
13.19.3. Product & Services
13.20. PHC Corporation
13.20.1. Business Overview
13.20.2. Key Executives
13.20.3. Product & Services
13.21. Sanofi S.A.
13.21.1. Business Overview
13.21.2. Key Executives
13.21.3. Product & Services
13.22. Takeda Pharmaceutical Company Limited
13.22.1. Business Overview
13.22.2. Key Executives
13.22.3. Product & Services
13.23. Teva Pharmaceutical Industries Ltd.
13.23.1. Business Overview
13.23.2. Key Executives
13.23.3. Product & Services
13.24. TONGHUA DONGBAO PHARMACEUTICAL CO., LTD.
13.24.1. Business Overview
13.24.2. Key Executives
13.24.3. Product & Services
13.25. Wockhardt Limited
13.25.1. Business Overview
13.25.2. Key Executives
13.25.3. Product & Services
14. Appendix
14.1. Discussion Guide
14.2. License & Pricing